Physiologic and Pathophysiologic Effects of Angiotensin in the Heart and Vessel Wall

  • Richard E. Pratt
Part of the Basic Science for the Cardiologist book series (BASC, volume 2)


Angiotensin II (Ang II) exerts a majority of its known cardiovascular activities through the AT1 receptor. This receptor is a member of the 7-transmembrane superfamily and it exerts its actions via coupling to various G-proteins. Its downstream effectors include adenylate-cyclase, various phospholipases and ion channels. Moreover, various tyrosine kinase pathways have been reported to be activated by the AT1 receptor which result in the stimulation of the early response genes controlling cell growth. This action has been observed in several cell lines including cardiac myocytes and vascular smooth muscle cells. Moreover, studies strongly implicate the renin angiotensin system in the initiation and progression of atherosclerosis. Therefore, blockade of this system should influence not only vascular tone but may also have dramatic effects on vascular and cardiac structure.


Angiotensin Convert Enzyme Vascular Smooth Muscle Cell Angiotensin Convert Enzyme Inhibitor Arterioscler Thromb Vasc Biol Angiotensin Convert Enzyme Activity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 62:749–56, 1988.PubMedGoogle Scholar
  2. 2.
    Naftilan AJ, Pratt RE, Eldridge CS, Lin HL, Dzau VJ. Angiotensin II induces c-fos expression in smooth muscle via transcriptional control. Hypertension 13:706–11, 1989.PubMedGoogle Scholar
  3. 3.
    Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth muscle cells. J Clin Invest 83:1419–24, 1989.PubMedGoogle Scholar
  4. 4.
    Gibbons GH, Pratt RE, Dzau VJ. Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest 90:456–61, 1992.PubMedGoogle Scholar
  5. 5.
    Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91:2268–74, 1993.PubMedGoogle Scholar
  6. 6.
    Duff JL, Marrero MB, Paxton WG, Schieffer B, Bernstein KE, Berk BC. Angiotensin II signal transduction and the mitogen-activated protein kinase pathway. Cardiovasc Res 30:511–7, 1995.PubMedGoogle Scholar
  7. 7.
    Berk BC. Angiotensin II signal transduction in vascular smooth muscle: pathways activated by specific tyrosine kinases [In Process Citation]. J Am Soc Nephrol 10Suppl 11:S62–8, 1999.Google Scholar
  8. 8.
    Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375:247–50, 1995.PubMedGoogle Scholar
  9. 9.
    Marrero MB, Schieffer B, Paxton WG, Duff JL, Berk BC, Bernstein KE. The role of tyrosine phosphorylation in angiotensin II-mediated intracellular signalling. Cardiovasc Res 30:530–6, 1995.PubMedGoogle Scholar
  10. 10.
    Inagami T, Eguchi S, Numaguchi K, Motley ED, Tang H, Matsumoto T, Yamakawa T. Cross-talk between angiotensin II receptors and the tyrosine kinases and phosphatases [In Process Citation]. J Am Soc Nephrol 10Suppl 11:S57–61, 1999.Google Scholar
  11. 11.
    Eguchi S, Iwasaki H, Inagami T, Numaguchi K, Yamakawa T, Motley ED, Owada KM, Marumo F, Hirata Y. Involvement of PYK2 in Angiotensin II Signaling of Vascular Smooth Muscle Cells. Hypertension 33:201–206, 1999.PubMedGoogle Scholar
  12. 12.
    Koibuchi Y, Lee WS, Gibbons GH, Pratt RE. Role of transforming growth factor-beta 1 in the cellular growth response to angiotensin II. Hypertension 21:1046–50, 1993.PubMedGoogle Scholar
  13. 13.
    Du J, Delafontaine P. Inhibition of vascular smooth muscle cell growth through antisense transcription of a rat insulin-like growth factor I receptor cDNA. Circ Res 76:963–72, 1995.PubMedGoogle Scholar
  14. 14.
    Delafontaine P, Lou H. Angiotensin II regulates insulin-like growth factor I gene expression in vascular smooth muscle cells. J Biol Chem 268:16866–70, 1993.PubMedGoogle Scholar
  15. 15.
    Owens GK. Differential effects of antihypertensive drug therapy on vascular smooth muscle cell hypertrophy, hyperploidy, and hyperplasia in the spontaneously hypertensive rat. Circ Res 56:525–36, 1985.PubMedGoogle Scholar
  16. 16.
    Owens GK. Influence of blood pressure on development of aortic medial smooth muscle hypertrophy in spontaneously hypertensive rats. Hypertension 9:178–87, 1987.PubMedGoogle Scholar
  17. 17.
    Daemen MJ, Lombardi DM, Bosman FT, Schwartz SM. Angiotensin II induces smooth muscle cell proliferation in the normal and injured rat arterial wall. Circ Res 68:450–6, 1991.PubMedGoogle Scholar
  18. 18.
    Su EJ, Lombardi DM, Siegal J, Schwartz SM. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 31:1331–7, 1998.PubMedGoogle Scholar
  19. 19.
    Su EJ, Lombardi DM, Wiener J, Daemen MJ, Reidy MA, Schwartz SM. Mitogenic effect of angiotensin II on rat carotid arteries and type II or III mesenteric microvessels but not type I mesenteric microvessels is mediated by endogenous basic fibroblast growth factor. Circ Res 82:321–7, 1998.PubMedGoogle Scholar
  20. 20.
    Rakugi H, Jacob HJ, Krieger JE, Ingelfinger JR, Pratt RE. Vascular injury induces angiotensinogen gene expression in the media and neointima. Circulation 87:283–90, 1993.PubMedGoogle Scholar
  21. 21.
    Rakugi H, Wang DS, Dzau VJ, Pratt RE. Potential importance of tissue angiotensin-converting enzyme inhibition in preventing neointima formation. Circulation 90:449–55, 1994.PubMedGoogle Scholar
  22. 22.
    Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ, Pratt RE. Induction of angiotensin converting enzyme in the neointima after vascular injury. Possible role in restenosis. J Clin Invest 93:339–46, 1994.PubMedGoogle Scholar
  23. 23.
    Powell JS, Clozel JP, Muller RK, Kuhn H, Hefti F, Hosang M, Baumgartner HR. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 245:186–8, 1989.PubMedGoogle Scholar
  24. 24.
    Kawamura M, Terashita Z, Okuda H, Imura Y, Shino A, Nakao M, Nishikawa K. TCV-116, a novel angiotensin II receptor antagonist, prevents intimai thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther 266:1664–9, 1993.PubMedGoogle Scholar
  25. 25.
    Abe J, Deguchi J, Matsumoto T, Takuwa N, Noda M, Ohno M, Makuuchi M, Kurokawa K, Takuwa Y. Stimulated activation of platelet-derived growth factor receptor in vivo in balloon-injured arteries: a link between angiotensin II and intimai thickening. Circulation 96:1906–13, 1997.PubMedGoogle Scholar
  26. 26.
    Osterrieder W, Muller RK, Powell JS, Clozel JP, Hefti F, Baumgartner HR. Role of angiotensin II in injury-induced neointima formation in rats. Hypertension 18:II60–4, 1991.PubMedGoogle Scholar
  27. 27.
    Wiemer G, Scholkens BA, Wagner A, Heitsch H, Linz W. The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. J Hypertens Suppl 11 Suppl 5:S234–5, 1993.Google Scholar
  28. 28.
    Schuh JR, Blehm DJ, Frierdich GE, McMahon EG, Blaine EH. Differential effects of renin-angiotensin system blockade on atherogenesis in cholesterol-fed rabbits. J Clin Invest 91:1453–8, 1993.PubMedGoogle Scholar
  29. 29.
    Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res 68:106–13, 1991.PubMedGoogle Scholar
  30. 30.
    Lindner V, Reidy MA. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc Natl Acad Sci U S A 88:3739–43, 1991.PubMedGoogle Scholar
  31. 31.
    Lindner V, Olson NE, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest 90:2044–9, 1992.PubMedGoogle Scholar
  32. 32.
    Fishel RS, Thourani V, Eisenberg SJ, Shai SY, Corson MA, Nabel EG, Bernstein KE, Berk BC. Fibroblast growth factor stimulates angiotensin converting enzyme expression in vascular smooth muscle cells. Possible mediator of the response to vascular injury. J Clin Invest 95:377–87, 1995.PubMedGoogle Scholar
  33. 33.
    Chobanian AV. The effects of ACE inhibitors and other antihypertensive drugs on cardiovascular risk factors and atherogenesis. Clin Cardiol 13:VII43–8, 1990.PubMedGoogle Scholar
  34. 34.
    Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 15:327–31, 1990.PubMedGoogle Scholar
  35. 35.
    Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction [see comments]. Nature 359:641–4, 1992.PubMedGoogle Scholar
  36. 36.
    Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr., Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators [see comments]. N Engl J Med 327:669–77, 1992.PubMedGoogle Scholar
  37. 37.
    Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors [published erratum appears in N Engl J Med 1992 Dec 10;327(24):1768] [see comments]. N Engl J Med 327:685–91, 1992.Google Scholar
  38. 38.
    Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators [see comments]. N Engl J Med 325:293–302, 1991.Google Scholar
  39. 39.
    Kaplan HR, Taylor DG, Olson SC, Andrews LK. Quinapril—a preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiology 40:335–50, 1989.PubMedGoogle Scholar
  40. 40.
    Weishaar RE, Panek RL, Major TC, Simmerman J, Rapundalo ST, Taylor DG, Jr. Evidence for a functional tissue renin-angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure. J Pharmacol Exp Ther 256:568–74, 1991.PubMedGoogle Scholar
  41. 41.
    Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE. The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 99:2375–85, 1997.PubMedGoogle Scholar
  42. 42.
    Morishita R, Gibbons GH, Ellison KE, Lee W, Zhang L, Yu H, Kaneda Y, Ogihara T, Dzau VJ. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 94:978–84, 1994.PubMedGoogle Scholar
  43. 43.
    Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH, Dzau VJ. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94:2756–67, 1996.PubMedGoogle Scholar
  44. 44.
    Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD. Evidence that angiotensin II is present in human monocytes. Circulation 91:1129–34, 1995.PubMedGoogle Scholar
  45. 45.
    Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol 271:H1065–71, 1996.PubMedGoogle Scholar
  46. 46.
    Hoshida S, Nishida M, Yamashita N, Igarashi J, Aoki K, Hori M, Kuzuya T, Tada M. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis 130:53–9, 1997.PubMedGoogle Scholar
  47. 47.
    Haberbosch W, Bohle RM, Franke FE, Danilov S, Alhenc-Gelas F, Braun-Dullaeus R, Holschermann H, Waas W, Tillmanns H, Gardemann A. The expression of angiotensin-I converting enzyme in human atherosclerotic plaques is not related to the deletion/insertion polymorphism but to the risk of restenosis after coronary interventions. Atherosclerosis 130:203–13, 1997.PubMedGoogle Scholar
  48. 48.
    Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta P, Mehta JL. Increased angiotensin II type 1 receptor expression in hypercholesterolemic atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol 18:1433–9, 1998.PubMedGoogle Scholar
  49. 49.
    Cardona-Sanclemente LE, Medina R, Born GV. Effect of increasing doses of angiotensin II infused into normal and hypertensive Wistar rats on low density lipoprotein and fibrinogen uptake by aortic walls. Proc Natl Acad Sci U S A 91:3285–8, 1994.PubMedGoogle Scholar
  50. 50.
    Cardona-Sanclemente LE, Born GV. Increase by adrenaline or angiotensin II of the accumulation of low density lipoprotein and fibrinogen by aortic walls in unrestrained conscious rats. Br J Pharmacol 117:1089–94, 1996.PubMedGoogle Scholar
  51. 51.
    Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Effect of angiotensin II and enalapril on transfer of low-density lipoprotein into aortic intima in rabbits. Circ Res 75:63–9, 1994.PubMedGoogle Scholar
  52. 52.
    Keidar S, Kaplan M, Shapira C, Brook JG, Aviram M. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 107:71–84, 1994.PubMedGoogle Scholar
  53. 53.
    Keidar S, Kaplan M, Hoffman A, Aviram M. Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 115:201–15, 1995.PubMedGoogle Scholar
  54. 54.
    Scheidegger KJ, Butler S, Witztum JL. Angiotensin II increases macrophage-mediated modification of low density lipoprotein via a lipoxygenase-dependent pathway. J Biol Chem 272:21609–15, 1997.PubMedGoogle Scholar
  55. 55.
    Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol 16:97–105, 1996.PubMedGoogle Scholar
  56. 56.
    Hernandez-Presa M, Bustos C, Ortego M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 95:1532–41, 1997.PubMedGoogle Scholar
  57. 57.
    Mervaala EM, M ller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension [In Process Citation]. Hypertension 33:389–95, 1999.PubMedGoogle Scholar
  58. 58.
    Grafe M, Auch-Schwelk W, Zakrzewicz A, Regitz-Zagrosek V, Bartsch P, Graf K, Loebe M, Gaehtgens P, Fleck E. Angiotensin II-induced leukocyte adhesion on human coronary endothelial cells is mediated by E-selectin [In Process Citation]. Circ Res 81:804–11, 1997.PubMedGoogle Scholar
  59. 59.
    Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97:1916–23, 1996.PubMedGoogle Scholar
  60. 60.
    Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages [In Process Citation]. Hypertension 33:335–9, 1999.PubMedGoogle Scholar
  61. 61.
    Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 32:488–95, 1998.PubMedGoogle Scholar
  62. 62.
    Ushio-Fukai M, Zafari AM, Fukui T, Ishizaka N, Griendling KK. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317–21, 1996.PubMedGoogle Scholar
  63. 63.
    Khan BV, Harrison DG, Olbrych MT, Alexander RW, Medford RM. Nitric oxide regulates vascular cell adhesion molecule 1 gene expression and redox-sensitive transcriptional events in human vascular endothelial cells. Proc Natl Acad Sci U S A 93:9114–9, 1996.PubMedGoogle Scholar
  64. 64.
    Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest 92:1866–74, 1993.PubMedGoogle Scholar
  65. 65.
    Candipan RC, Wang BY, Buitrago R, Tsao PS, Cooke JP. Regression or progression. Dependency on vascular nitric oxide. Arterioscler Thromb Vasc Biol 16:44–50, 1996.PubMedGoogle Scholar
  66. 66.
    Wang BY, Candipan RC, Arjomandi M, Hsiun PT, Tsao PS, Cooke JP. Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits. J Am Coll Cardiol 28:1573–9, 1996.PubMedGoogle Scholar
  67. 67.
    Tsao PS, Wang B, Buitrago R, Shyy JY, Cooke JP. Nitric oxide regulates monocyte chemotactic protein-1. Circulation 96:934–40, 1997.PubMedGoogle Scholar
  68. 68.
    Theilmeier G, Chan JR, Zalpour C, Anderson B, Wang BY, Wolf A, Tsao PS, Cooke JP. Adhesiveness of mononuclear cells in hypercholesterolemic humans is normalized by dietary L-arginine. Arterioscler Thromb Vase Biol 17:3557–64, 1997.Google Scholar
  69. 69.
    Whitebread S, Mele M, Kamber B, de Gasparo M. Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163:284–91, 1989.PubMedGoogle Scholar
  70. 70.
    Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL, et al. Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 165:196–203, 1989.PubMedGoogle Scholar
  71. 71.
    Sugano M, Makino N, Yanaga T. The effects of renin-angiotensin system inhibition on aortic cholesterol content in cholesterol-fed rabbits. Atherosclerosis 127:123–9, 1996.PubMedGoogle Scholar
  72. 72.
    Keidar S, Attias J, Smith J, Breslow JL, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun 236:622–5, 1997.PubMedGoogle Scholar
  73. 73.
    Fennessy PA, Campbell JH, Mendelsohn FA, Campbell GR. Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol 23:S30–2, 1996.PubMedGoogle Scholar
  74. 74.
    Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, Matsuda Y, Inagami T. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 351:230–3, 1991.PubMedGoogle Scholar
  75. 75.
    Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 351:233–6, 1991.PubMedGoogle Scholar
  76. 76.
    Sasamura H, Hein L, Krieger JE, Pratt RE, Kobilka BK, Dzau VJ. Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome. Biochem Biophys Res Commun 185:253–9, 1992.PubMedGoogle Scholar
  77. 77.
    Iwai N, Inagami T. Quantitative analysis of renin gene expression in extrarenal tissues by polymerase chain reaction method. J Hypertens 10:717–24, 1992.PubMedGoogle Scholar
  78. 78.
    Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 88:921–33, 1991.PubMedGoogle Scholar
  79. 79.
    Millan MA, Jacobowitz DM, Aguilera G, Cart KJ. Differential distribution of AT1 and AT2 angiotensin II receptor subtypes in the rat brain during development. Proc Natl Acad Sci USA 88:11440–4, 1991.PubMedGoogle Scholar
  80. 80.
    Pucell AG, Hodges JC, Sen I, Bumpus FM, Husain A. Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology 128:1947–59, 1991.PubMedGoogle Scholar
  81. 81.
    Tsutsumi K, Saavedra JM. Characterization and development of angiotensin II receptor subtypes (ATI and AT2) in rat brain. Am J Physiol 261:R209–16, 1991.PubMedGoogle Scholar
  82. 82.
    Dudley DT, Hubbell SE, Summerfelt RM. Characterization of angiotensin II (AT2) binding sites in R3T3 cells. Mol Pharmacol 40:360–7, 1991.PubMedGoogle Scholar
  83. 83.
    Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268:24543–6, 1993.PubMedGoogle Scholar
  84. 84.
    Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268:24539–42, 1993.PubMedGoogle Scholar
  85. 85.
    Viswanathan M, Tsutsumi K, Correa FM, Saavedra JM. Changes in expression of angiotensin receptor subtypes in the rat aorta during development. Biochem Biophys Res Commun 179:1361–7, 1991.PubMedGoogle Scholar
  86. 86.
    Hutchinson HG, Hein L, Fuginaga M, Pratt RE. Modulation of vascular development and injury by angiotensin II. Cardiovascular Research In Press 1998.Google Scholar
  87. 87.
    Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, Horiuchi M, Pratt RE, Dzau VJ. The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 92:10663–7, 1995.PubMedGoogle Scholar
  88. 88.
    Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95:651–7, 1995.PubMedGoogle Scholar
  89. 89.
    Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension 28:635–40, 1996.PubMedGoogle Scholar
  90. 90.
    Bartunek J, Weinberg EO, Tajima M, Rohrbach S, Lorell BH. Angiotensin II type 2 receptor blockade amplifies the early signals of cardiac growth response to angiotensin II in hypertrophied hearts [In Process Citation]. Circulation 99:22–5, 1999.PubMedGoogle Scholar
  91. 91.
    Cook CL, Weiser MC, Schwartz PE, Jones CL, Majack RA. Developmentally timed expression of an embryonic growth phenotype in vascular smooth muscle cells. Circ Res 74:189–96, 1994.PubMedGoogle Scholar
  92. 92.
    deBlois D, Tea BS, Than VD, Tremblay J, Hamet P. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 29:340–9, 1997.PubMedGoogle Scholar
  93. 93.
    Bennett MR, Evan GI, Schwartz SM. Apoptosis of rat vascular smooth muscle cells is regulated by p53-dependent and-independent pathways. Circ Res 77:266–73, 1995.PubMedGoogle Scholar
  94. 94.
    Cheng W, Kajstura J, Nitahara JA, Li B, Reiss K, Liu Y, Clark WA, Krajewski S, Reed JC, Olivetti G, Anversa P. Programmed myocyte cell death affects the viable myocardium after infarction in rats. Exp Cell Res 226:316–27, 1996.PubMedGoogle Scholar
  95. 95.
    Hamet P. Proliferation and apoptosis of vascular smooth muscle in hypertension. Curr Opin Nephrol Hypertens 4:1–7, 1995.PubMedGoogle Scholar
  96. 96.
    Isner JM, Kearney M, Bortman S, Passeri J. Apoptosis in human atherosclerosis and restenosis [see comments]. Circulation 91:2703–11, 1995.PubMedGoogle Scholar
  97. 97.
    Kajstura J, Cheng W, Reiss K, Clark WA, Sonnenblick EH, Krajewski S, Reed JC, Olivetti G, Anversa P. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 74:86–107, 1996.PubMedGoogle Scholar
  98. 98.
    Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA. Apoptosis in myocytes in end-stage heart failure [see comments]. N Engl J Med 335:1182–9, 1996.PubMedGoogle Scholar
  99. 99.
    Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 79:748–56, 1996.PubMedGoogle Scholar
  100. 100.
    Hamet P, deBlois D, Dam TV, Richard L, Teiger E, Tea BS, Orlov SN, Tremblay J. Apoptosis and vascular wall remodeling in hypertension. Can J Physiol Pharmacol 74:850–61, 1996.PubMedGoogle Scholar
  101. 101.
    Wu CF, Bishopric NH, Pratt RE. Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 272:14860–6, 1997.PubMedGoogle Scholar
  102. 102.
    Trindade P, Hutchinson HG, Pollman MJ, Gibbons GH, Pratt RE. Atrial Natriuretic Peptide (ANP) and C-type Natriuretic Peptide (CNP) induce apoptosis in vascular smooth muscle cells. Circulation 92:I–696 (Abstract), 1995.Google Scholar
  103. 103.
    Balligand JL, Cannon PJ. Nitric oxide synthases and cardiac muscle. Autocrine and paracrine influences. Arterioscler Thromb Vasc Biol 17:1846–58, 1997.PubMedGoogle Scholar
  104. 104.
    Colucci WS. Molecular and cellular mechanisms of myocardial failure. Am J Cardiol 80:15L–25L, 1997.PubMedGoogle Scholar
  105. 105.
    Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-1 beta-converting enzyme [see comments]. Am J Pathol 147:251–66, 1995.PubMedGoogle Scholar
  106. 106.
    Kajstura J, Cigola E, Malhotra A, Li P, Cheng W, Meggs LG, Anversa P. Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol29:859–70, 1997.PubMedGoogle Scholar
  107. 107.
    Pierzchalski P, Reiss K, Cheng W, Cirielli C, Kajstura J, Nitahara JA, Rizk M, Capogrossi MC, Anversa P. p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system. Exp Cell Res 234:57–65, 1997.PubMedGoogle Scholar
  108. 108.
    Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 272:19022–6, 1997.PubMedGoogle Scholar
  109. 109.
    Horiuchi M, Yamada T, Hayashida W, Dzau VJ. Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. J Biol Chem 272:11952–8, 1997.PubMedGoogle Scholar
  110. 110.
    Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 93:156–60, 1996.PubMedGoogle Scholar
  111. 111.
    Leri A, Claudio PP, Li Q, Wang X, Reiss K, Wang S, Malhotra A, Kajstura J, Anversa P. Stretch-mediated release of angiotensin II induces myocyte apoptosis by activating p53 that enhances the local renin-angiotensin system and decreases the Bcl-2-to-Bax protein ratio in the cell. J Clin Invest 101:1326–42, 1998.PubMedGoogle Scholar
  112. 112.
    Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I. Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 53:937–44, 1998.PubMedGoogle Scholar
  113. 113.
    Koch WJ, Hawes BE, Allen LF, Lefkowitz RJ. Direct evidence that Gi-coupled receptor stimulation of mitogen-activated protein kinase is mediated by G beta gamma activation of p21ras. Proc Natl Acad Sci USA91:12706–10, 1994.PubMedGoogle Scholar
  114. 114.
    Zhang J, Pratt RE. The AT2 receptor selectively associates with Gialpha2 and Gialpha3 in the rat fetus. J Biol Chem 271:15026–33, 1996.PubMedGoogle Scholar
  115. 115.
    Siragy HM, Carey RM. The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100:264–9, 1997.PubMedGoogle Scholar
  116. 116.
    Siragy HM, Carey RM. The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3’, 5’-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats [see comments]. J Clin Invest 97:1978–82, 1996.PubMedGoogle Scholar
  117. 117.
    Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31:349–55, 1998.PubMedGoogle Scholar
  118. 118.
    Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. J Clin Invest 99:1926–35, 1997.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Richard E. Pratt
    • 1
  1. 1.Brigham and Women’s HospitalUSA

Personalised recommendations